Ethosuximide
产品说明书
 |
同义名 : | CI-366; Zarontin; Emeside, Ethosuccimid, Ethosuximide, Ethylmethylsuccimide, Ethymal, Zarontin.; NSC 64013 |
| CAS号 : | 77-67-8 | |
| 货号 : | A320514 | |
| 分子式 : | C7H11NO2 | |
| 纯度 : | 98% | |
| 分子量 : | 141.17 | |
| MDL号 : | MFCD00072123 | |
| 存储条件： |
Pure form Inert atmosphere, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Ethosuximide, 2-ethyl-2-methylsuccinimide, has been used extensively for "petit mal" seizures. Commonly observed side effects of ethosuximide are dose dependent and involve the gastrointestinal tract and central nervous system. The spontaneous pacemaker oscillatory activity of thalamocortical circuitry involves low threshold T-type Ca2+ currents in the thalamus, and ethosuximide is presumed to reduce these low threshold T-type Ca2+ currents in thalamic neurons. Ethosuximide also decreases the persistent Na+ and Ca2+ -activated K+ currents in thalamic and layer V cortical pyramidal neurons[3]. Ethosuximide and valproic acid are more effective than lamotrigine in the treatment of childhood absence epilepsy. Ethosuximide is associated with fewer adverse attentional effects[4]. Concentrations of 2 μM or more of Ethosuximide not only are found to be less effective than 1 μM concentration of Ethosuximide, but also induce cell toxicity. The number and percentage of tubulin β-III immunopositive neurons were increased after 6 days treatment with ethosuximide. Ethosuximide may compensate damage caused by seizure attacks and possibly other neuronal loss disorders[5]. Ethosuximide given with drinking water (300 mg/kg/day) over 45 days slightly reduced proneness to audiogenic epilepsy and increased locomotor activity of the animals at the periphery of the open field[6]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02205931 | Epilepsy | Phase 4 | Recruiting | June 2019 | United Kingdom ... 展开 >> Birmingham Children's Hospital Recruiting Birmingham, United Kingdom, B4 6NH Contact: Shakti Agrawal, MBBS 0044 1213338149 shakti.agrawal@bch.nhs.uk Principal Investigator: Shakti Agrawal, MBBS Bristol Royal Hospital for Children Recruiting Bristol, United Kingdom, BS2 8AE Contact: Andrew Mallick, FRCPCH Principal Investigator: Andrew Mallick Addenbrooke's Hospital Recruiting Cambridge, United Kingdom, CB2 0QQ Contact: Alasdair Parker, MA 0044 1223 245151 alasdair.parker@addenbrookes.nhs.uk Principal Investigator: Alasdair Parker, MA Lancashire Teaching Hospitals NHS Foundation Trust Recruiting Lancashire, United Kingdom Contact: Helen Basu Helen.Basu@lthtr.nhs.uk Principal Investigator: Helen Basu Leeds Teaching Hospital Recruiting Leeds, United Kingdom, LS1 3EX Contact: Helen McCullagh, RCPCH 0044 113 243 2799 h.mccullagh@nhs.net Principal Investigator: Helen McCullagh, RCPCH Alder Hey Children's Hospital Recruiting Liverpool, United Kingdom, L12 2AP Contact: Rachel Kneen, BMBS 0044 151 2525163 rachel.kneen@liverpool.ac.uk Principal Investigator: Rachel Kneen, BMBS Great Ormond Street Hospital Recruiting London, United Kingdom, WC1N 3JH Contact: Christin Eltze, MD Res 0044 207 405 9200 ext 5438 christin.eltze@gosh.nhs.uk Principal Investigator: Christin Eltze, MD Res St George's University Hospitals NHS Foundation Trust Recruiting London, United Kingdom Contact: Penny Fallon Penny.Fallon@stgeorges.nhs.uk Principal Investigator: Penny Fallon Royal Manchester Children's Hospital Recruiting Manchester, United Kingdom, M13 0JE Contact: Tim Martland, RCPCH 0044 161 276 1234 timothy.martland@cmft.nhs.uk Principal Investigator: Tim Martland, RCPCH The Newcastle Upon Tyne Hospitals NHS Foundation Trust Recruiting Newcastle upon Tyne, United Kingdom Contact: Anita Devlin Anita.Devlin@nuth.nhs.uk Principal Investigator: Anita Devlin Sheffield Children's NHS Foundation Trust Recruiting Sheffield, United Kingdom Contact: Archana Desurkar Archana.Desurkar@sch.nhs.uk Principal Investigator: Archana Desurkar 收起 << |
| NCT01390909 | - | Completed | - | - | |
| NCT01390909 | - | Completed | - | - | |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
7.08mL 1.42mL 0.71mL |
35.42mL 7.08mL 3.54mL |
70.84mL 14.17mL 7.08mL |
| 参考文献 |
|---|
|
[3]Gören MZ, Onat F. Ethosuximide: from bench to bedside. CNS Drug Rev. 2007 Summer;13(2):224-39 |